Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

Sorted by: relevance · author · university · dateNew search

You searched for subject:(obstetric pharmacology). Showing records 1 – 2 of 2 total matches.

Search Limiters

Last 2 Years | English Only

No search limiters apply to these results.

▼ Search Limiters


University of Washington

1. Dorfman, Elizabeth Howard. Translational Research in Obstetric Pharmacology: Historical Trends, Prenatal Pharmacogenomics, and an Opportunistic Study of Placental ABCG2 and Fetal Glyburide Exposure.

Degree: PhD, 2015, University of Washington

This dissertation is principally comprised of three distinct but related projects. The first is an assessment of the quantity and nature of obstetric pharmacology clinical trials conducted in the past decade, as well as a comparison of these trials to non-obstetric trials, in order to identify whether the challenges and complexities of conducting research in this field are reflected in the aggregate study data available through ClinicalTrials.gov. The analysis identified several significant differences between obstetric and non-obstetric trials, which have implications for program planning and funding needs. Second is an overview of the ways in which the fetal genome may be informative of fetal outcomes with regard to medication and other chemical exposures during pregnancy, and the attendant research prioritization of this area and clinical testing opportunities made possible by non-invasive prenatal genetic tests that utilize cell-free fetal DNA in a pregnant woman’s blood. Finally, an opportunistic clinical study was conducted, assessing whether fetal genotype for the placental efflux transporter breast cancer resistance protein (BCRP, ABCG2) is predictive of relative fetal exposure to the oral hypoglycemic agent glyburide, which is used, off-label as an alternative to insulin, to treat gestational diabetes. The results of the study showed no association between fetal ABCG2 Q141K genotype and relative glyburide exposure at term, which was unexpected given the extensive, albeit indirect, supporting evidence that formed the basis of the initial hypothesis. This result has clinical implications related to the optimal use of glyburide to treat gestational diabetes, and also underscores the complexity of drug disposition during pregnancy and the need to study pregnant women directly. Advisors/Committee Members: Thummel, Kenneth E (advisor).

Subjects/Keywords: ABCG2; breast cancer resistance protein; fetal drug exposure; glyburide; obstetric pharmacology; placental drug transport; Genetics; Pharmacology; Obstetrics and gynecology; public health genetics

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Dorfman, E. H. (2015). Translational Research in Obstetric Pharmacology: Historical Trends, Prenatal Pharmacogenomics, and an Opportunistic Study of Placental ABCG2 and Fetal Glyburide Exposure. (Doctoral Dissertation). University of Washington. Retrieved from http://hdl.handle.net/1773/34161

Chicago Manual of Style (16th Edition):

Dorfman, Elizabeth Howard. “Translational Research in Obstetric Pharmacology: Historical Trends, Prenatal Pharmacogenomics, and an Opportunistic Study of Placental ABCG2 and Fetal Glyburide Exposure.” 2015. Doctoral Dissertation, University of Washington. Accessed April 15, 2021. http://hdl.handle.net/1773/34161.

MLA Handbook (7th Edition):

Dorfman, Elizabeth Howard. “Translational Research in Obstetric Pharmacology: Historical Trends, Prenatal Pharmacogenomics, and an Opportunistic Study of Placental ABCG2 and Fetal Glyburide Exposure.” 2015. Web. 15 Apr 2021.

Vancouver:

Dorfman EH. Translational Research in Obstetric Pharmacology: Historical Trends, Prenatal Pharmacogenomics, and an Opportunistic Study of Placental ABCG2 and Fetal Glyburide Exposure. [Internet] [Doctoral dissertation]. University of Washington; 2015. [cited 2021 Apr 15]. Available from: http://hdl.handle.net/1773/34161.

Council of Science Editors:

Dorfman EH. Translational Research in Obstetric Pharmacology: Historical Trends, Prenatal Pharmacogenomics, and an Opportunistic Study of Placental ABCG2 and Fetal Glyburide Exposure. [Doctoral Dissertation]. University of Washington; 2015. Available from: http://hdl.handle.net/1773/34161


Universitat de Barcelona

2. Torres Ferraz, Rosa. Pla de desenvolupament d’una nova combinació de fàrmacs pel tractament de la Síndrome de l’Ovari Poliquístic: del mercat al mercat.

Degree: 2018, Universitat de Barcelona

There is currently no drug approved specifically for the treatment of Polycystic Ovary Syndrome (PCOS), one of the most common endocrine disorder of reproductive-aged women, with a growing prevalence and characterized by complex pathophysiology with an interplay of multiple factors. The scientific community has highlighted the need to increase the research for new treatments aimed primarily at normalizing the endocrine-metabolic features underlying the syndrome, this would represent a new paradigm in the treatment of PCOS that would reduce the known long-term morbidities, and therefore the socioeconomic impact of this syndrome. The use in combination of two insulin sensitizing drugs and an antiandrogenic drug has shown in the last decade to be promising therapeutic approach able to improve PCOS symptomatology through the reduction of hepato-visceral fat. Taking advantage of the available evidence, and the growing interest in PCOS, it is proposed to develop a new fixed-dose combination drug of the three known active ingredients and to design a viable and optimal development plan for a new drug application in Europe (EU) and United States of America (USA). The pharmaceutical development based on quality by design and focused on the fixed dose combination of the three active ingredients (50mg spironolactone, 7.5mg pioglitazone, 850mg metformin; SPIOMET) has enabled the development of a viable and stable formulation of the new SPIOMET tablets for oral administration, with a comparable bioavailability to the existing individual reference products. The proposed clinical development plan has been based on the available evidence of the use of the three drugs administered as individual products or co-administered in PCOS as the main basis of the clinical evidence of SPIOMET and has been submitted in a scientific advice with European (EMA) and American (FDA) drug agencies. The resulting clinical plan includes a sequence of Phase I, II and III studies that should allow to demonstrate the safety and the effectiveness of SPIOMET with a favorable risk-benefit ratio for the future authorization of the new PCOS treatment in EU and USA. Overall, thanks to the scientific and regulatory rational supporting the project, the development plan designed could be more accelerated and with less investment than other innovative products for new indications, in a scenario that no unexpected technical results or unforeseen changes in regulation occurred and with a proper use of the resources. This turns SPIOMET into a differential and very attractive project. Advisors/Committee Members: Universitat de Barcelona. Facultat de Farmàcia i Ciències de l'Alimentació, rosat[email protected] (authoremail), false (authoremailshow), Campàs Moya, Clara (director), Ibáñez Toda, Lourdes (director), García López, María Luisa (tutor).

Subjects/Keywords: Malalties dels ovaris; Enfermedades de los ovarios; Ovary diseases; Endocrinologia; Endocrinología; Endocrinology; Farmacologia obstètrica; Farmacología obstétrica; Obstetric pharmacology; Ciències de la Salut; 615

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Torres Ferraz, R. (2018). Pla de desenvolupament d’una nova combinació de fàrmacs pel tractament de la Síndrome de l’Ovari Poliquístic: del mercat al mercat. (Thesis). Universitat de Barcelona. Retrieved from http://hdl.handle.net/10803/664862

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Torres Ferraz, Rosa. “Pla de desenvolupament d’una nova combinació de fàrmacs pel tractament de la Síndrome de l’Ovari Poliquístic: del mercat al mercat.” 2018. Thesis, Universitat de Barcelona. Accessed April 15, 2021. http://hdl.handle.net/10803/664862.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Torres Ferraz, Rosa. “Pla de desenvolupament d’una nova combinació de fàrmacs pel tractament de la Síndrome de l’Ovari Poliquístic: del mercat al mercat.” 2018. Web. 15 Apr 2021.

Vancouver:

Torres Ferraz R. Pla de desenvolupament d’una nova combinació de fàrmacs pel tractament de la Síndrome de l’Ovari Poliquístic: del mercat al mercat. [Internet] [Thesis]. Universitat de Barcelona; 2018. [cited 2021 Apr 15]. Available from: http://hdl.handle.net/10803/664862.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Torres Ferraz R. Pla de desenvolupament d’una nova combinació de fàrmacs pel tractament de la Síndrome de l’Ovari Poliquístic: del mercat al mercat. [Thesis]. Universitat de Barcelona; 2018. Available from: http://hdl.handle.net/10803/664862

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

.